The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tada, T.
Right arrow Articles by Hamaoka, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tada, T.
Right arrow Articles by Hamaoka, T.

The Journal of Immunology, Vol 146, Issue 3 1077-1082, Copyright © 1991 by American Association of Immunologists


ARTICLES

Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state

T Tada, S Ohzeki, K Utsumi, H Takiuchi, M Muramatsu, XF Li, J Shimizu, H Fujiwara and T Hamaoka
Biomedical Research Center, Osaka University Medical School, Japan.

The present study investigates the nature of humoral component(s) generated in tumor-bearing hosts to induce immune dysfunction of T cells. Cell-free ascitic fluid and culture supernatant (SN) were obtained from the ascites and cultures allowing MH134 hepatoma cells to grow. These ascites and SN samples were tested for their abilities to influence the generation of CTL responses to TNP and alloantigens. The generation of the anti-TNP CTL responses that require self H-2- restricted CD4+ Th cells was markedly suppressed by addition of the ascites or SN under conditions in which these samples did not inhibit anti-allo CTL responses capable of using alternate pathways of allo- restricted CD4+ and CD8+ Th. The activation of CD8+ CTL precursors and CTL activity were also resistant to the ascites or SN. The ascites- or SN-induced suppressive effect to which CD4+ Th were most susceptible was found to be mediated by transforming growth factor-beta (TGF-beta) activity, because: 1) the TGF-beta activity was detected in the MH134 ascites and culture SN; 2) the suppression of CD4+ Th function required for anti-TNP CTL responses was almost completely prevented by addition of anti-TGF-beta antibody to cultures and; 3) rTGF-beta also induced similar patterns of immunosuppression to those observed by ascites or SN. These results indicate that TGF-beta produced by tumor cells induces deleterious effects on T cell, especially on the CD4+ Th subset, and provide an explanation for the molecular mechanism underlying the previously observed CD4+ Th-selective suppression in the tumor-bearing state.


This article has been cited by other articles:


Home page
J Bone Joint Surg BrHome page
H. Nishida, H. Tsuchiya, and K. Tomita
Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma
J Bone Joint Surg Br, September 1, 2008; 90-B(9): 1249 - 1255.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Hojo, K. Koizumi, K. Tsuneyama, Y. Arita, Z. Cui, K. Shinohara, T. Minami, I. Hashimoto, T. Nakayama, H. Sakurai, et al.
High-Level Expression of Chemokine CXCL16 by Tumor Cells Correlates with a Good Prognosis and Increased Tumor-Infiltrating Lymphocytes in Colorectal Cancer
Cancer Res., May 15, 2007; 67(10): 4725 - 4731.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al.
TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction
J. Immunol., May 15, 2007; 178(10): 6642 - 6652.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher Jr., S. J. Yokota, and R. B. Bankert
Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells
J. Immunol., May 1, 2007; 178(9): 5552 - 5562.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. A. Willemsen, Z. Sebestyen, C. Ronteltap, C. Berrevoets, J. Drexhage, and R. Debets
CD8{alpha} Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10
J. Immunol., July 15, 2006; 177(2): 991 - 998.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M.-L. Cheng, H.-W. Chen, J.-P. Tsai, Y.-P. Lee, Y.-C. Shih, C.-M. Chang, and C.-C. Ting
Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}
J. Leukoc. Biol., May 1, 2006; 79(5): 1033 - 1042.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. A. Rohn, A. Reitz, A. Paschen, X. D. Nguyen, D. Schadendorf, A. B. Vogt, and H. Kropshofer
A Novel Strategy for the Discovery of MHC Class II-Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope
Cancer Res., November 1, 2005; 65(21): 10068 - 10078.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Tsuji, M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, et al.
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes
Blood, July 15, 2005; 106(2): 470 - 476.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Takeuchi, S.-i. Hiraoka, X.-Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara
Anti-HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice
Cancer Res., October 15, 2004; 64(20): 7588 - 7595.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda
Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity
Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg
Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease
Cancer Res., March 15, 2004; 64(6): 2205 - 2211.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Gyobu, T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, et al.
Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor
Cancer Res., February 15, 2004; 64(4): 1490 - 1495.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Chamoto, T. Tsuji, H. Funamoto, A. Kosaka, J. Matsuzaki, T. Sato, H. Abe, K. Fujio, K. Yamamoto, T. Kitamura, et al.
Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells
Cancer Res., January 1, 2004; 64(1): 386 - 390.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Tsuboi, K. Saijo, E. Ishikawa, H. Tsurushima, S. Takano, Y. Morishita, and T. Ohno
Effects of Local Injection of ex Vivo Expanded Autologous Tumor-specific T Lymphocytes in Cases with Recurrent Malignant Gliomas
Clin. Cancer Res., August 1, 2003; 9(9): 3294 - 3302.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Yanagisawa, K.-i. Seino, Y. Ishikawa, M. Nozue, T. Todoroki, and K. Fukao
Impaired Proliferative Response of V{alpha}24 NKT Cells from Cancer Patients Against {alpha}-Galactosylceramide
J. Immunol., June 15, 2002; 168(12): 6494 - 6499.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. G. S. Buggins, D. Milojkovic, M. J. Arno, N. C. Lea, G. J. Mufti, N. S. B. Thomas, and W. J. R. Hirst
Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-{kappa}B, c-Myc, and pRb Pathways
J. Immunol., November 15, 2001; 167(10): 6021 - 6030.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, and G. J. Hammerling
NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides
J. Immunol., November 1, 2001; 167(9): 5247 - 5253.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Tsushima, N. Ito, S. Tamura, Y. Matsuda, M. Inada, I. Yabuuchi, Y. Imai, R. Nagashima, H. Misawa, H. Takeda, et al.
Circulating Transforming Growth Factor {beta}1 as a Predictor of Liver Metastasis after Resection in Colorectal Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1258 - 1262.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
A. Takahashi, K. Kono, H. Amemiya, H. Iizuka, H. Fujii, and Y. Matsumoto
Elevated Caspase-3 Activity in Peripheral Blood T Cells Coexists with Increased Degree of T-Cell Apoptosis and Down-Regulation of TCR Zeta Molecules in Patients with Gastric Cancer
Clin. Cancer Res., January 1, 2001; 7(1): 74 - 80.
[Abstract] [Full Text]


Home page
Jpn J Clin OncolHome page
H. Nakayama, J. Kitayama, T. Muto, and H. Nagawa
Characterization of Intracellular Cytokine Profile of CD4(+) T Cells in Peripheral Blood and Tumor-draining Lymph Nodes of Patients with Gastrointestinal Cancer
Jpn. J. Clin. Oncol., July 1, 2000; 30(7): 301 - 305.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. McKallip, R. Li, and S. Ladisch
Tumor Gangliosides Inhibit the Tumor-Specific Immune Response
J. Immunol., October 1, 1999; 163(7): 3718 - 3726.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. E. Gordinier, H.-Z. Zhang, R. Patenia, L. B. Levy, E. N. Atkinson, M. A. Nash, R. L. Katz, C. D. Platsoucas, and R. S. Freedman
Quantitative Analysis of Transforming Growth Factor {beta}1 and 2 in Ovarian Carcinoma
Clin. Cancer Res., September 1, 1999; 5(9): 2498 - 2505.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Komatsu, L. Yee, and K. L. Carraway
Overexpression of Sialomucin Complex, a Rat Homologue of MUC4, Inhibits Tumor Killing by Lymphokine-activated Killer Cells
Cancer Res., May 1, 1999; 59(9): 2229 - 2236.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. K. Sandberg, P. Grufman, E. Z. Wolpert, L. Franksson, B. J. Chambers, and K. Karre
Superdominance Among Immunodominant H-2Kb-Restricted Epitopes and Reversal by Dendritic Cell-Mediated Antigen Delivery
J. Immunol., April 1, 1998; 160(7): 3163 - 3169.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
P. L. Fidel Jr, R. Romero, J. Cutright, N. Wolf, R. Gomez, H. Araneda, M. Ramirez, and B. H. Yoon
Treatment With the Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein Does Not Prevent Endotoxin-Induced Preterm Parturition in Mice
Reproductive Sciences, January 1, 1997; 4(1): 22 - 26.
[Abstract] [PDF]


Home page
LupusHome page
G. Del Giudice and M. K. Crow
Review: Role of Transforming Growth Factor Beta (TGF{beta}) in Systemic Autoimmunity
Lupus, August 1, 1993; 2(4): 213 - 220.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.